FTB Advisors Inc. boosted its position in shares of Shire PLC (NASDAQ:SHPG) by 3.1% during the second quarter, Holdings Channel reports. The institutional investor owned 600 shares of the biopharmaceutical company’s stock after buying an additional 18 shares during the period. FTB Advisors Inc.’s holdings in Shire PLC were worth $110,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of SHPG. BlackRock Fund Advisors raised its position in shares of Shire PLC by 10.0% in the first quarter. BlackRock Fund Advisors now owns 591,458 shares of the biopharmaceutical company’s stock valued at $101,672,000 after buying an additional 53,889 shares during the period. NN Investment Partners Holdings N.V. bought a new position in shares of Shire PLC during the first quarter valued at approximately $1,014,000. Bessemer Group Inc. raised its position in shares of Shire PLC by 1,854.4% in the first quarter. Bessemer Group Inc. now owns 3,088 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 2,930 shares during the period. M&T Bank Corp raised its position in shares of Shire PLC by 33.8% in the first quarter. M&T Bank Corp now owns 6,601 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 1,668 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Shire PLC by 5.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,728 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 82 shares during the period. 24.30% of the stock is owned by institutional investors and hedge funds.
Shire PLC (NASDAQ:SHPG) traded down 0.83% during mid-day trading on Wednesday, hitting $189.12. 770,528 shares of the company were exchanged. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32. The stock’s 50 day moving average is $194.55 and its 200-day moving average is $188.26. The company has a market cap of $56.33 billion, a price-to-earnings ratio of 39.30 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the previous year, the company earned $2.63 earnings per share. The business’s revenue was up 55.9% compared to the same quarter last year. Equities research analysts predict that Shire PLC will post $12.92 EPS for the current year.
The firm also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
SHPG has been the subject of several research analyst reports. Zacks Investment Research raised shares of Shire PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 4th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a research note on Wednesday, September 7th. BTIG Research reiterated a “buy” rating and set a $230.00 price objective on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research note on Monday, August 1st. Five research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $228.15.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.